Anti-diabetic potential of Panax notoginseng saponins (PNS): A review

Phytotherapy Research

Volumn 28, Issue 4, 2014, Pages 510-516

  Uzayisenga, Rosette ^a,b   Ayeka, Peter Amwoga ^a,c   Wang, Yi ^a  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b District Pharmacy Ministry of Health   (Rwanda)

^c EGERTON UNIVERSITY   (Kenya)

Author keywords

diabetes mellitus; Panax notoginseng; Panax notoginseng saponins

Indexed keywords

GINSENOSIDE RB 1; GINSENOSIDE RD; GINSENOSIDE RE; GINSENOSIDE RG 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; IMMUNOLOGICAL ADJUVANT; INSULIN; METFORMIN; NOTOGINSENOSIDE R1; PANAX NOTOGINSENG SAPONIN; PHENFORMIN; PIOGLITAZONE; SAPONIN DERIVATIVE; SULFONYLUREA; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARALIACEAE; ASIA; CARDIOVASCULAR DISEASE; CHINA; CHINESE MEDICINE; DIABETES MELLITUS; DIABETOGENESIS; DRUG STRUCTURE; GLUCONEOGENESIS; GLUCOSE ABSORPTION; HERB; HERBAL MEDICINE; HUMAN; INFLAMMATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANAX NOTOGINSENG; PATIENT CARE; REVIEW; SAN QI; TIANQI;

ARALIACEAE; PANAX NOTOGINSENG;

DIABETES MELLITUS; PANAX NOTOGINSENG; PANAX NOTOGINSENG SAPONINS;

ANIMALS; ANTI-OBESITY AGENTS; CHINA; DIABETES MELLITUS; DRUGS, CHINESE HERBAL; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY; PANAX NOTOGINSENG; PLANT ROOTS; PLANTS, MEDICINAL; SAPONINS;

EID: 84897975038     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5026     Document Type: Review

References (83)

1. Abraira C, Colwell JA, Nuttall FQ, et al,. 1995. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 18: 1113-1123.
2. Ang-Lee MK, Moss J, Yuan CS,. 2001. Herbal medicines and perioperative care. JAMA 286: 208-216.
3. Attele AS, Wu JA, Yuan CS,. 1999. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58: 1685-1693.
4. Attele AS, Zhou YP, Xie JT, et al,. 2002. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes 51: 1851-1858.
5. Australia D,. 2007. National priorities for turning around the diabetes epidemic 2007-2008. Diabetes Australia, Canberra. www.diabetesaustralia.com.au/- lib/doc-pdf/news/Priorities-2007.pdf.
6. Aziz A, Wheatcroft S,. 2011. Insulin resistance in Type 2 diabetes and obesity: implications for endothelial function. Expert Rev Cardiovasc Ther 9: 403-407.
7. Bell DS,. 2001. Importance of postprandial glucose control. South Med J 94: 804-809.
8. Campbell KE, Caudill MA, Spalding TW, Liang MT,. 2007. Four weeks of panax notoginseng supplementation has no effect on blood glucose in non-diabetic adults: 2057: board #127 may 31 3:30 PM-5:00 PM. Med Sci Sports Exerc 39: S361-S361.
9. Chaturvedi P,. 2012. Antidiabetic potentials of Momordica charantia: multiple mechanisms behind the effects. J Med Food 15: 101-107.
10. Chen ZH, Li J, Liu J, et al,. 2008. Saponins isolated from the root of Panax notoginseng showed significant anti-diabetic effects in KK-Ay mice. Am J Chin Med 36: 939-951.
11. Christensen LP,. 2009. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res 55: 1-99.
12. Coman C, Rugina OD, Socaciu C,. 2012. Plants and Natural Compounds with Antidiabetic Action. Not Bot Hort Agrobot Cluj 40: 314-325.
13. Court WE,. 2000. Ginseng: the history of an insignificant plant. Pharm Hist (Lond) 30: 38-44.
14. Cui XM, Lo CK, Yip KL, Dong TT, Tsim KW,. 2003. Authentication of Panax notoginseng by 5S-rRNA spacer domain and random amplified polymorphic DNA (RAPD) analysis. Planta Med 69: 584-586.
15. Defronzo RA,. 1999. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131: 281-303.
16. Dong TT, Cui XM, Song ZH, et al,. 2003. Chemical assessment of roots of Panax notoginseng in China: regional and seasonal variations in its active constituents. J Agric Food Chem 51: 4617-4623.
17. Du Q, Jerz G, Waibel R, Winterhalter P,. 2003. Isolation of dammarane saponins from Panax notoginseng by high-speed counter-current chromatography. J Chromatogr A 1008: 173-180.
18. Edwin E, Sheeja E, Gupta V, Jain D,. 2006. Fight Diabetes the herbal way. Express Pharma Pulse 1: 41-42.
19. Eliason BC, Kruger J, Mark D, Rasmann DN,. 1997. Dietary supplement users: demographics, product use, and medical system interaction. J Am Board Fam Pract 10: 265-271.
20. Haffner SM,. 2003. Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract 61 (Suppl 1): S9-S18.
21. Harnack LJ, Rydell SA, Stang J,. 2001. Prevalence of use of herbal products by adults in the Minneapolis/St Paul, Minn, metropolitan area. Mayo Clin Proc 76: 688-694.
22. Huang KC,. 2010. The Pharmacology of Chinese Herbs (2nd edn). London, Taylor & Francis.
23. Jarald E, Joshi SB, Jain DC,. 2008. Diabetes and Herbal Medicines (Vol. 7).
24. Kahn BB, Alquier T, Carling D, Hardie DG,. 2005. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25.
25. Kim JJ, Xiao H, Tan Y, Wang ZZ, Paul Seale J, Qu X,. 2009. The effects and mechanism of saponins of Panax notoginseng on glucose metabolism in 3 T3-L1 cells. Am J Chin Med 37: 1179-1189.
26. Kim SJ, Yuan HD, Chung SH,. 2010. Ginsenoside Rg1 suppresses hepatic glucose production via AMP-activated protein kinase in HepG2 cells. Biol Pharm Bull 33: 325-328.
27. Kishida K, Funahashi T, Shimomura I,. 2012. Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin. Endocr Metab Immune Disord Drug Targets 12: 118-131.
28. Klein R, Klein BE, Moss SE, Cruickshanks KJ,. 1994. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 154: 2169-2178.
29. Kohei K,. 2010. Pathophysiology of Type 2 Diabetes and Its Treatment Policy. Jpn Med Assoc 53: 41-46.
30. Kuzuya T, Nakagawa S, Satoh J, et al,. 2002. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 55: 65-85.
31. Lang J, Cao H, Wei A,. 1998. Comparative study on effect of Panax notoginseng and ticlid in treating early diabetic nephropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi 18: 727-729.
32. Lau AJ, Toh DF, Chua TK, Pang YK, Woo SO, Koh HL,. 2009. Antiplatelet and anticoagulant effects of Panax notoginseng: comparison of raw and steamed Panax notoginseng with Panax ginseng and Panax quinquefolium. J Ethnopharmacol 125: 380-386.
33. Li L, Sheng Y, Zhang J, Guo D,. 2005a. Determination of four active saponins of Panax notoginseng in rat feces by high-performance liquid chromatography. J Chromatogr Sci 43: 421-425.
34. Li L, Zhang JL, Sheng YX, Guo DA, Wang Q, Guo HZ,. 2005b. Simultaneous quantification of six major active saponins of Panax notoginseng by high-performance liquid chromatography-UV method. J Pharm Biomed Anal 38: 45-51.
35. Li SH, Chu Y,. 1999. Anti-inflammatory effects of total saponins of Panax notoginseng. Zhongguo Yao Li Xue Bao 20: 551-554.
36. Li WL, Zheng HC, Bukuru J, De Kimpe N,. 2004. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol 92: 1-21.
37. Liu QZ, Pettitt DJ, Hanson RL, et al,. 1993. Glycated haemoglobin, plasma glucose and diabetic retinopathy: cross-sectional and prospective analyses. Diabetologia 36: 428-432.
38. Mahady GB, Gyllenhaal C, Fong HHS, Farnsworth NR,. 2000. Ginsengs: A Review of Safety and Efficacy. Nutr Clin Care 3: 90-101.
39. Matsuzawa Y,. 2006. The metabolic syndrome and adipocytokines. FEBS Lett 580: 2917-2921.
40. Ng TB,. 2006. Pharmacological activity of sanchi ginseng (Panax notoginseng). J Pharm Pharmacol 58: 1007-1019.
41. Ohkubo Y, Kishikawa H, Araki E, et al,. 1995. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117.
42. Ozcan U, Cao Q, Yilmaz E, et al,. 2004. Endoplasmic reticulum stress links obesity,insulin action and type 2 diabetes. Science 306: 457-461.
43. Park S, Ahn IS, Kwon DY, Ko BS, Jun WK,. 2008. Ginsenosides Rb1 and Rg1 suppress triglyceride accumulation in 3 T3-L1 adipocytes and enhance beta-cell insulin secretion and viability in Min6 cells via PKA-dependent pathways. Biosci Biotechnol Biochem 72: 2815-2823.
44. Perera PK, Li Y,. 2011. Mushrooms as a functional food mediator in Preventing and ameliorating diabetes. Funct Foods Health Dis 4: 161-171.
45. Qi LW, Wang CZ, Yuan CS,. 2011. Isolation and analysis of ginseng: advances and challenges. Nat Prod Rep 28: 467-495.
46. Quan HY, Yuan HD, Jung MS, Ko SK, Park YG, Chung SH,. 2012. Ginsenoside Re lowers blood glucose and lipid levels via activation of AMP-activated protein kinase in HepG2 cells and high-fat diet fed mice. Int J Mol Med 29: 73-80.
47. Reaven GM,. 1988. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607.
48. Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW, Ruderman NB,. 2004. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 314: 580-585.
49. Saini V,. 2010. Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes 1: 68-75.
50. Salas-Salvado J, Martinez-Gonzalez MA, Bullo M, Ros E,. 2011. The role of diet in the prevention of type 2 diabetes. Nutr Metab Cardiovasc Dis 21 (Suppl 2): B32-48.
51. Scaglione F, Ferrara F, Dugnani S, Falchi M, Santoro G, Fraschini F,. 1990. Immunomodulatory effects of two extracts of Panax ginseng C.A. Meyer. Drugs Exp Clin Res 16: 537-542.
52. Singh VK, Agarwal S, Gupta BM,. 1984. Immunomodulatory activity of Panax ginseng extract. Planta Med 50: 462-465.
53. Skyler JS,. 2004. Diabetes mellitus: pathogenesis and treatment strategies. J Med Chem 47: 4113-4117.
54. Stolk RP, Vingerling JR, de Jong PT, et al,. 1995. Retinopathy, glucose, and insulin in an elderly population. The Rotterdam Study. Diabetes 44: 11-15.
55. Stumvoll M, Goldstein BJ, van Haeften TW,. 2005. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365: 1333-1346.
56. Sun HX, Pan HJ, Pan YJ,. 2003. Haemolytic activities and immunologic adjuvant effect of Panax notoginseng saponins. Acta Pharmacol Sin 24: 1150-1154.
57. Tahrani AA, Piya MK, Kennedy A, Barnett AH,. 2010. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther 125: 328-361.
58. Taira S, Ikeda R, Yokota N, et al,. 2010. Mass spectrometric imaging of ginsenosides localization in Panax ginseng root. Am J Chin Med 38: 485-493.
59. Vuksan V, Sung MK, Sievenpiper JL, et al,. 2008. Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety. Nutr Metab Cardiovasc Dis 18: 46-56.
60. Wan JB, Yang FQ, Li SP, Wang YT, Cui XM,. 2006. Chemical characteristics for different parts of Panax notoginseng using pressurized liquid extraction and HPLC-ELSD. J Pharm Biomed Anal 41: 1596-1601.
61. Wang C-Z, McEntee E, Wicks S, Wu J-A, Yuan C-S,. 2006. Phytochemical and analytical studies of Panax notoginseng (Burk.) F.H. Chen. J Nat Med 60: 97-106.
62. Wang CZ, Xie JT, Zhang B, et al,. 2007. Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells. Int J Oncol 31: 1149-1156.
63. Wang N, Wan J, Li M, Wang Y,. 2008. Advances in studies on Panax notoginseng against atherosclerosis. Chin Tradit Herb Drugs 5: 787-791.
64. Wang R, Li YN, Wang GJ, Hao HP, Wu XL, Zhou F,. 2009. Neuroprotective Effects and brain transport of Ginsenoside Rg1. Chin J Nat Med 7: 315-320.
65. Wang X, Zheng Y, Fang J,. 2004. Reserch development of hypoglycemic polysaccharide and oligosaccharide. Acta Pharm Sin 39: 1028-1033.
66. Wang YL, Chen D, Wu JL,. 1994. Effects and mechanism of total saponins of Panax Notoginseng on anti-inflammation and analgesia. Zhongguo Zhong Xi Yi Jie He Za Zhi 14: 35-36.
67. Waugh N, Scotland G, McNamee P, et al,. 2007. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 11: 1-146.
68. White CM, Fan C, Chow M,. 2000. An evaluation of the hemostatic effect of externally applied notoginseng and notoginseng total saponins. J Clin Pharmacol 40: 1150-1153.
69. Wold L, Ceylan-Isik A, Ren J,. 2005. Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta Pharmacol Sin 26: 908-917.
70. World Health Organization. 2009. WHO Monographs on Selected Medicinal Plants, 1.
71. Xie JT, Mehendale SR, Li X, et al,. 2005. Anti-diabetic effect of ginsenoside Re in ob/ob mice. Biochim Biophys Acta 1740: 319-325.
72. Xiong Y, Shen L, Liu KJ, et al,. 2010. Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats. Diabetes 59: 2505-2512.
73. Yach D, Stuckler D, Brownell KD,. 2006. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 12: 62-66.
74. Yang CY, Wang J, Zhao Y, et al,. 2010. Anti-diabetic effects of Panax notoginseng saponins and its major anti-hyperglycemic components. J Ethnopharmacol 130: 231-236.
75. Yang CY, Xie ZG, Cheng WB, Jiang X, Chen ZH,. 2009. Effects of Panax notoginseng saponins on anti-hyperglycemic, anti-obese and prevention from kidney pathological changes in KK-Ay mice. Zhong Yao Cai 32: 1571-1576.
76. Yao XH, Li XJ,. 2001. Panax notoginseng saporins injection in treatment of cerebral infarction with a multicenter study. Chin J New Drugs Clin Rem 20: 257-260.
77. Yao XH, Li XJ,. 2002. Protective effects and its mechanism of panaxatriol saponins isolated from Panax notoginseng on cerebral ischemia. Zhongguo Zhong Yao Za Zhi 27: 371-373.
78. Yao Y, Sang W, Zhou M, Ren G,. 2010. Antioxidant and alpha-glucosidase inhibitory activity of colored grains in China. J Agric Food Chem 58: 770-774.
79. Zhang Y, Scarpace PJ,. 2006. The role of leptin in leptin resistance and obesity. Physiol Behav 88: 249-256.
80. Zhang Z, Li X, Lv W, et al,. 2008. Ginsenoside Re reduces insulin resistance through inhibition of c-Jun NH2-terminal kinase and nuclear factor-kappaB. Mol Endocrinol 22: 186-195.
81. Zhou G, Myers R, Li Y, et al,. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174.
82. Zhou JM, Ke JH,. 2000. The discussion on application of Panax notoginseng and Panax ginseng. Chin Tradit Herb Drugs 31: 2-3.
83. Zozulinska D, Wierusz-Wysocka B,. 2006. Type 2 diabetes mellitus as inflammatory disease. Diabetes Res Clin Pract 74: S12-S16.